- Home
- CENX vs TVTX Comparison
CENX vs TVTX Comparison
Compare CENX & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CENX
- TVTX
- Stock Information
- Founded
- CENX 1995
- TVTX 2008
- Country
- CENX United States
- TVTX United States
- Employees
- CENX N/A
- TVTX N/A
- Industry
- CENX Aluminum
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CENX Industrials
- TVTX Health Care
- Exchange
- CENX Nasdaq
- TVTX Nasdaq
- Market Cap
- CENX 1.5B
- TVTX 1.7B
- IPO Year
- CENX 1996
- TVTX N/A
- Fundamental
- Price
- CENX $15.88
- TVTX $20.02
- Analyst Decision
- CENX Strong Buy
- TVTX Strong Buy
- Analyst Count
- CENX 3
- TVTX 14
- Target Price
- CENX $23.00
- TVTX $33.31
- AVG Volume (30 Days)
- CENX 1.5M
- TVTX 1.5M
- Earning Date
- CENX 05-07-2025
- TVTX 05-01-2025
- Dividend Yield
- CENX N/A
- TVTX N/A
- EPS Growth
- CENX 35.22
- TVTX N/A
- EPS
- CENX 3.12
- TVTX N/A
- Revenue
- CENX $2,223,300,000.00
- TVTX $273,533,000.00
- Revenue This Year
- CENX $6.79
- TVTX $68.31
- Revenue Next Year
- CENX $3.58
- TVTX $55.65
- P/E Ratio
- CENX $5.15
- TVTX N/A
- Revenue Growth
- CENX 4.75
- TVTX 75.65
- 52 Week Low
- CENX $11.40
- TVTX $6.01
- 52 Week High
- CENX $25.39
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- CENX 44.66
- TVTX 58.32
- Support Level
- CENX $14.77
- TVTX $19.65
- Resistance Level
- CENX $17.57
- TVTX $22.07
- Average True Range (ATR)
- CENX 0.76
- TVTX 1.11
- MACD
- CENX 0.01
- TVTX 0.31
- Stochastic Oscillator
- CENX 39.50
- TVTX 69.58
About CENX Century Aluminum Company
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.